WO2003059249A3 - Nivalenol as specific inhibitor to transcriptional factor c-maf and pharmaceutical compositions comprising the same - Google Patents

Nivalenol as specific inhibitor to transcriptional factor c-maf and pharmaceutical compositions comprising the same Download PDF

Info

Publication number
WO2003059249A3
WO2003059249A3 PCT/KR2003/000099 KR0300099W WO03059249A3 WO 2003059249 A3 WO2003059249 A3 WO 2003059249A3 KR 0300099 W KR0300099 W KR 0300099W WO 03059249 A3 WO03059249 A3 WO 03059249A3
Authority
WO
WIPO (PCT)
Prior art keywords
nivalenol
maf
same
pharmaceutical compositions
specific inhibitor
Prior art date
Application number
PCT/KR2003/000099
Other languages
French (fr)
Other versions
WO2003059249A2 (en
Inventor
Chung-Yeon Choi
Yoon-Seok Chang
Yoon-Keun Kim
Kyeong-Eob Min
Sang-Hyeon Jo
In-Gyu Kim
Ju-Hong Jeon
Sang-Chul Park
Heun-Soo Kang
Original Assignee
Metabolic Engineering Lab Co L
Chung-Yeon Choi
Yoon-Seok Chang
Yoon-Keun Kim
Kyeong-Eob Min
Sang-Hyeon Jo
In-Gyu Kim
Ju-Hong Jeon
Sang-Chul Park
Heun-Soo Kang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Engineering Lab Co L, Chung-Yeon Choi, Yoon-Seok Chang, Yoon-Keun Kim, Kyeong-Eob Min, Sang-Hyeon Jo, In-Gyu Kim, Ju-Hong Jeon, Sang-Chul Park, Heun-Soo Kang filed Critical Metabolic Engineering Lab Co L
Priority to AU2003206148A priority Critical patent/AU2003206148A1/en
Publication of WO2003059249A2 publication Critical patent/WO2003059249A2/en
Publication of WO2003059249A3 publication Critical patent/WO2003059249A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to a pharmaceutical composition for treatment or prophylaxis of Th2 cytokine-related diseases, which comprises (a) a pharmaceutically effective dose of nivalenol as an inhibitor for the activity of IL-4, especially via c-Maf transcription factor inhibition, and (b) a pharmaceutically acceptable carrier.
PCT/KR2003/000099 2002-01-16 2003-01-16 Nivalenol as specific inhibitor to transcriptional factor c-maf and pharmaceutical compositions comprising the same WO2003059249A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003206148A AU2003206148A1 (en) 2002-01-16 2003-01-16 Nivalenol as specific inhibitor to transcriptional factor c-maf and pharmaceutical compositions comprising the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2002-0002573A KR100485271B1 (en) 2002-01-16 2002-01-16 Nivalenol as a specific inhibitor of the transcriptional factor, c-maf and pharmaceutical compositions comprising the same
KR2002/2573 2002-01-16

Publications (2)

Publication Number Publication Date
WO2003059249A2 WO2003059249A2 (en) 2003-07-24
WO2003059249A3 true WO2003059249A3 (en) 2003-11-27

Family

ID=19718528

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2003/000099 WO2003059249A2 (en) 2002-01-16 2003-01-16 Nivalenol as specific inhibitor to transcriptional factor c-maf and pharmaceutical compositions comprising the same

Country Status (3)

Country Link
KR (1) KR100485271B1 (en)
AU (1) AU2003206148A1 (en)
WO (1) WO2003059249A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2626431T3 (en) 2010-10-06 2015-12-21 Fundació Inst De Recerca Biomèdica Irb Barcelona A process for the diagnosis, prognosis and treatment of breast cancer metastasis
EP2650682A1 (en) 2012-04-09 2013-10-16 Fundació Privada Institut de Recerca Biomèdica Method for the prognosis and treatment of cancer metastasis
MX368513B (en) 2012-06-06 2019-10-07 Fundacio Inst De Recerca Biomedica Irb Barcelona Method for the diagnosis, prognosis and treatment of lung cancer metastasis.
US10119171B2 (en) 2012-10-12 2018-11-06 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
WO2014057357A2 (en) 2012-10-12 2014-04-17 Inbiomotion S.L. Method for the diagnosis, prognosis and treatment of prostate cancer metastasis
MX368575B (en) 2013-03-15 2019-10-08 Fundacio Inst De Recerca Biomedica Irb Barcelona Method for the diagnosis, prognosis and treatment of cancer metastasis.
AU2017271385B2 (en) 2016-05-25 2023-10-05 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-MAF status
US11654153B2 (en) 2017-11-22 2023-05-23 Inbiomotion S.L. Therapeutic treatment of breast cancer based on c-MAF status

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3935842A1 (en) * 1989-10-27 1991-05-08 Licentia Gmbh Large liquid crystal display device - uses thermal conductors to transfer heat from back light to rear wall of display housing
US5146354A (en) * 1991-05-07 1992-09-08 Compaq Computer Corporation LCD system with a backlight having a light source at a light pipe's edge and with the LCD enframed
US6392724B2 (en) * 2000-02-24 2002-05-21 Lg. Philips Lcd Co., Ltd. LCD module having improved fixing structure

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118612A (en) * 1987-04-28 1992-06-02 Wisconsin Alumni Research Foundation Assay for trichothecenes

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3935842A1 (en) * 1989-10-27 1991-05-08 Licentia Gmbh Large liquid crystal display device - uses thermal conductors to transfer heat from back light to rear wall of display housing
US5146354A (en) * 1991-05-07 1992-09-08 Compaq Computer Corporation LCD system with a backlight having a light source at a light pipe's edge and with the LCD enframed
US6392724B2 (en) * 2000-02-24 2002-05-21 Lg. Philips Lcd Co., Ltd. LCD module having improved fixing structure

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHOI C.Y. ET AL.: "Nivalenol inhibits total and antigen-specific IgE production in mice", accession no. STN Database accession no. 133:100756 *
TOXICOLOGY AND APPLIED PHARMACOLOGY, vol. 165, no. 1, 2000, pages 94 - 98 *

Also Published As

Publication number Publication date
KR20030062137A (en) 2003-07-23
KR100485271B1 (en) 2005-04-27
AU2003206148A1 (en) 2003-07-30
WO2003059249A2 (en) 2003-07-24
AU2003206148A8 (en) 2003-07-30

Similar Documents

Publication Publication Date Title
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
CA2504735A1 (en) Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
MXPA05013224A (en) Pyridinyl carbamates as hormone-sensitive lipase inhibitors.
MXPA04012965A (en) Viral inhibitors.
WO2002046129A3 (en) Inhibitors of histone deacetylase
MY120064A (en) Indole derivatives as inhibitors or factor xa
HK1057899A1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
WO2004014322A3 (en) Immunomodulatory compositions, methods of making, and methods of use thereof
HK1087702A1 (en) Arylmethylamine derivatives for use as tryptase inhibitors
WO2003080070A3 (en) Combination comprising an hmg-coa reductase inhibittor and an insulin secretor enhancer or an insulin sensitizer
WO2004004632A3 (en) Flavone derivatives as inhibitors of cyclin-dependent kinases
WO2004037789A8 (en) Methylene urea derivatives as raf-kinase inhibitors
WO2003106381A3 (en) Human adam-10 inhibitors
AU2002363182A1 (en) Smad7 inhibitors for the treatment of cns diseases
AU2001230395A1 (en) Use of cox-2 inhibitors as gastroprokinetics
WO2004039803A3 (en) Hiv-integrase inhibitors, pharmaceutical compositions, and methods for their use
WO2003059249A3 (en) Nivalenol as specific inhibitor to transcriptional factor c-maf and pharmaceutical compositions comprising the same
WO2003087062A3 (en) 4-(heterocyclyl)-benzenesulfoximine compounds for the treatment of inflammation
MY130792A (en) 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES
MXPA05013226A (en) Substituted piperidine carbamates for use as inhibitors of hormone sensitive lipase.
MXPA05001469A (en) Use of fermented wheat germ extract as anti-inflammatory agent.
AU2003249930A1 (en) Proteaseome inhibitors for the treatment of herpesviridae infected individuals
WO2004060878A3 (en) Inhibitors of phosphatases
WO2002096870A3 (en) Sponge-derived terpenoids and methods of use
WO2000048447A3 (en) Composition for treatment of external secretion disorders except hypolacrimation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP